Antibody Ingredients TRIZ Cases

Fcabs bind dimeric CD137 with high affinity, avoiding dose-limiting liver inflammation.

CLEVER-1 antibodies switch M2 macrophages to M1, reducing systemic toxicities from non-specific therapies.

Anti-HER3 antibodies bind human HER3 with high affinity to block neuregulin interaction and induce receptor degradation.

Humanized antibodies targeting CSF-1R block ligand binding and induce receptor degradation, resolving cross-reactivity failures in murine models.

Heated air evaporation during wet granulation maintains protein stability while improving manufacturing efficiency.

MOR00208 targets CD19 with enhanced ADCC via Fc engineering, improving survival in low NK cell patients.

Combining anti-CD37 and anti-CD20 antibodies with Fc-Fc interaction enhancing substitutions induces highly efficient complement-dependent cytotoxicity.

HW1 and HW6 antibodies target DR5 to induce autophagic cell death, overcoming resistance in TRAIL-resistant cancer cells.

A superantigen conjugate links targeting moieties to immune cells for precise cancer antigen recognition.

VHH-based compounds target NKp30 receptors to activate natural killer cells, bypassing natural ligand interference that limits conventional antibody efficacy.

Fully human antibodies targeting apical membrane antigen 1 neutralize Plasmodium falciparum multiplication without inducing immunological rejection.

Antibodies targeting FGFR4 eliminate resistant colon cancer stem cells, preventing relapse and metastasis.

Optimized anti-PD-L1 antibody variable regions resolve low tumor expression bottlenecks by increasing signal inhibition efficacy.

Bispecific antibody blocks CD47-SIRPα checkpoint to resolve off-target toxicity while eliminating CD20+ lymphoma cells.

Human antibodies bind VEGFR-2 receptors to block ligand interaction and neutralize activation.

Segmenting immune checkpoints via anti-CEACAM6 and anti-TIM3 antibodies overcomes single-agent inhibition limits, boosting IFN-gamma secretion.

Multispecific molecules combine distinct binding moieties to target immunosuppressive myeloid cells.

Anti-Siglec-5 antibodies bind distinct epitopes to reduce Siglec-5 expression without inhibiting ligand binding, while triggering immune activation.

Recombinant Endo-D mutants transfer oligosaccharides to GlcNAc acceptors, producing homogeneous glycoproteins.

Antibody complementarity determining region optimization resolves the trade-off between therapeutic efficacy and structural complexity to improve durability.

Anti-NRP2b antibodies bind NRP2b variants 4 and 5 with high affinity, resolving isoform selectivity issues by minimizing cross-reactivity with NRP2a.

Optimized anti-KIR antibody formulations achieve sustained NK cell activation and tumor killing by maintaining continuous receptor occupancy.

NILO1 monoclonal antibody detects early neural progenitors in the subventricular zone niche.

Antibodies targeting NOTCH receptors block ligand activation to treat cancer stem cells.

Antibody conjugates bind BCMA to deliver payloads, resolving efficacy and specificity trade-offs in multiple myeloma treatment.

Anti-canine PD-1 antibody binds canine PD-1 protein, blocking immune checkpoint signaling that limits human antibody efficacy in dogs.

Engineered monoclonal antibodies block HLA-G receptor interactions to recruit immune cells against tumors.

Anti-CEACAM1 antibody targets the N-domain to activate immune functions while avoiding cross-reactivity with CEACAM3, CEACAM5, CEACAM6, and CEACAM8.

A diagnostic method quantifies dipeptidyl peptidase 3 levels in bodily fluids to guide clinical interventions.

Anti-LYPD3 antibodies resolve normal tissue binding adverse effects by recognizing short chain O-glycans present on cancer cells.

Merges MSCs with CTLA4Ig to block co-stimulatory signals, inducing T cell anergy and prolonging graft survival in autoimmune conditions.

Fully human anti-PD-L1 antibodies featuring specific CDR sequences resolve suboptimal clinical performance and stability issues found in existing treatments.

Engineered antibodies target conserved PD-1 epitopes across species to inhibit tumor growth.

Multi-epitope antibody combinations overcome resistant cancer phenotypes by achieving synergistic inhibition of the MET signaling pathway.

Humanized anti-CD70 antibodies with specific framework mutations inhibit CD70-induced regulatory T cell signaling and enhance antitumor efficacy.

Dupilumab blocks IL-4 signaling pathways to treat moderate-to-severe allergic contact dermatitis without broad immunosuppression side effects.

Step dosing of CD33xCD3 bispecific constructs escalates dosage to mitigate cytokine release syndrome.

Using HE4 as a mediator biomarker avoids antibody competition for accurate monitoring.

Segmented single-domain antibodies resolve specificity and affinity trade-offs for targeted cancer therapy.

Felzartamab reduces anti-HLA antibodies while sparing regulatory B cells, resolving graft survival contradictions.

Segmenting full antibodies into nanobodies improves solid tumor penetration while maintaining specificity for macrophage mannose receptor imaging.

Altered antibody variable regions increase binding affinity and blocking capacity to reduce adverse effects like pain and anemia.

Targeted amino acid mutations in the Fc region improve binding affinity to Fcγ receptors, resolving low therapeutic efficacy and production cost bottlenecks.

A fully human anti-HER2 monoclonal antibody binds HER2 receptors with high affinity.

Segmented ILT3xCD3 agents bridge immune cells to destroy tumors while sparing normal stem cells.

Modified bispecific antibodies prevent off-target liver toxicity by activating only tumor-infiltrating lymphocytes expressing both 4-1BB and OX40 receptors.

Monoclonal antibodies inhibit plasmin activity by binding to unique protease domain loops.